Encorafenib Binimetinib and Cetuximab Regimen Improves Survival in BRAF CRC

Encorafenib, Binimetinib, and Cetuximab Regimen Improves Survival in BRAF+ CRC

Encorafenib, binimetinib, and cetuximab demonstrated a significant improvement in overall survival compared with cetuximab and an irinotecan-containing regimen in patients with BRAF-mutant colorectal cancer.

More From BioPortfolio on "Encorafenib, Binimetinib, and Cetuximab Regimen Improves Survival in BRAF+ CRC"